This is because after three years of PSA screening, men with cancer-predisposing BRCA2 variants proved to have a higher incidence of prostate cancer, were younger at diagnosis, and were more likely to have clinically significant tumours. The gene discussed is KLK3; the disease is prostate carcinoma.